ReiThera srl

ReiThera Srl is a CDMO specialized in the development of scalable processes and GMP manufacturing of viral vectors for gene therapies, genetic vaccines, and advanced therapy medicinal products (ATMP). With extensive expertise in viral vector production—including Adeno-Associated Virus (AAV), Adenoviral Vector (AdV), Vaccinia lineage vectors, Lentivirus, and Herpes Simplex Vector—ReiThera supports the clinical translation of innovative therapies. The company state-of-the-art facility in Rome, Italy is equipped with stirred-tank bioreactors ranging from 2L to 2000L, fixed-bed bioreactors for adherent cell growth, filling suites, and advanced quality control laboratories. ReiThera’s manufacturing capabilities cover both small- and large-scale production, ensuring rapid transitions from laboratory to clinical and commercial GMP-grade material by using validated platform including:

• Adenoviral GRAd platform: proprietary GRAd platform for vector generation, Production Cell Lines, fast process verification and transfer to GMP, validated GMP processes at different scales, fill & finish, Validated analytical methods

• Vaccinia lineage platform: MVA vector strains, production Cell Lines, Validated manufacturing process at different scale in a GMP class B area, fill & finish, Validated analytical SOP

• ReicellAAV Cell Line for AAV vector production for Gene Therapy.

ReiThera has demonstrated its ability to respond quickly to global health challenges through collaborations with research institutes, pharmaceutical companies, and international partners, solidifying its position as a leading Italian company in the biotechnology sector.

ReiThera has successfully contributed to consortia in past and current European programs (FP7, H2020, Horizon EU) and other National and International calls in the field of vaccines for infectious diseases and advanced gene therapies.